![]() |
UMIN-CTR Clinical Trial |
|
![]() |
![]() |
![]() |
![]() |
Name: | UMIN ID: |
Recruitment status | Enrolling by invitation |
Unique ID issued by UMIN | UMIN000027821 |
Receipt No. | R000031865 |
Scientific Title | Phase II study of allogeneic hematopoietic cell transplantation for children with acute myeloid leukemia in first and second complete remission using fludarabine, cytarabine, melphalan and low-dose total body irradiation as a conditioning regimen (AML-SCT15). |
Date of disclosure of the study information | 2017/07/01 |
Last modified on | 2017/12/19 |
Basic information | |||
Public title | Phase II study of allogeneic hematopoietic cell transplantation for children with acute myeloid leukemia in first and second complete remission using fludarabine, cytarabine, melphalan and low-dose total body irradiation as a conditioning regimen (AML-SCT15). | ||
Acronym | AML-SCT5 | ||
Scientific Title | Phase II study of allogeneic hematopoietic cell transplantation for children with acute myeloid leukemia in first and second complete remission using fludarabine, cytarabine, melphalan and low-dose total body irradiation as a conditioning regimen (AML-SCT15). | ||
Scientific Title:Acronym | AML-SCT5 | ||
Region |
|
Condition | |||
Condition | acute myeloid leukemia (AML) | ||
Classification by specialty |
|
||
Classification by malignancy | Malignancy | ||
Genomic information | YES |
Objectives | |
Narrative objectives1 | To investigate safety and efficacy of reduced-intensity/toxicity stem cell transplantation using fludarabine, cytarabine, melphalan and low-dose total body irradiation as a substantial myeloablative conditioning regimen (FLAMEL) for children with high-risk AML in first complete remission or AML in second complete remission. |
Basic objectives2 | Safety,Efficacy |
Basic objectives -Others | |
Trial characteristics_1 | Confirmatory |
Trial characteristics_2 | Pragmatic |
Developmental phase | Phase II |
Assessment | |
Primary outcomes | Probability of overall survival rate at three years after transplantation |
Key secondary outcomes | 1) Efficacy
Probability of event-free survival (EFS) rate, Cumulative incidence of relapse and non-relapse mortality (NRM) at 3 years after transplantation Probability of overall survival (OS) rate, EFS rate, Cumulative incidence of relapse and NRM at 10 years after transplantation Profile of cause of death at 3 and 10 years after transplantation Incidence of second transplantation and second malignant neoplasms 2) Short-term safety (up to 100 days after transplantation) Cumulative incidence of engraftment, secondary graft failure (2nd GF) and NRM at 100 days after transplantation Cumulative incidence and severity of acute and chronic graft-versus-host disease (GVHD), sinusoidal obstruction syndrome (SOS) and thrombotic microangiopathy (TMA) Incidence of and reason for donor lymphocyte infusion (DLI) Monitoring of chimerism at 1 and 3 months after FLAMEL regimen Profile of severe infectious disease after KIR ligand-mismatched cord blood transplantation Profile of conditioning regimen-related toxicities (Bearman criteria) up to 4 weeks after transplantation Profile of CTCAE (grade >=3) Cumulative days of fever (>=38C) 3) Long-term safety Cumulative incidence of engraftment, 2nd GF, SOS and TMA up to 1 year after transplantation Incidence of and reason for DLI up to one year after transplantation Cumulative incidence and severity of acute and chronic GVHD Monitoring of height (SD) and body weight (SD) after transplantation Monitoring of height (SD) of patients untreated with growth hormone Monitoring of TSH, free-T4, LH, FSH, testosterone, estradiol and anti-mullerian hormone Monitoring of Tanner stage and menstruation Incidence of growth disturbance, thyroid dysfunction and gonadal dysfunction at 3 and 10 years after transplantation Profile of CTCAE (grade >=3) up to 1 year after transplantation |
Base | |
Study type | Interventional |
Study design | |
Basic design | Parallel |
Randomization | Non-randomized |
Randomization unit | |
Blinding | Open -no one is blinded |
Control | Active |
Stratification | NO |
Dynamic allocation | NO |
Institution consideration | Institution is not considered as adjustment factor. |
Blocking | |
Concealment | No need to know |
Intervention | ||
No. of arms | 2 | |
Purpose of intervention | Treatment | |
Type of intervention |
|
|
Interventions/Control_1 | FLAMEL regimen: fludarabine (30 mg/m^2 x 1/day for 4 days), cytarabine (2 g/m^2 x 1/day for 4 days), melphalan (60 mg/m^2 x 1/day for 3 days) and low-dose total body irradiation (2 Gy x 1/day for one day)
Graft: any of bone marrow, peripheral stem cell and cord blood. Graft-versus-host disease (GVHD) prophylaxis: in essentially tacrolimus or cyclosporine in combination with methotrexate. |
|
Interventions/Control_2 | For evaluation of secondary endo-points, patients received allogeneic transplantation using myeloablative conditioning regimens consisting of busulfan (> 8 mg/kg) or total body irradiation (>= 8 Gy, fractionated) are also enrolled to this study.
Graft: any of bone marrow, peripheral stem cell and cord blood. Graft-versus-host disease (GVHD) prophylaxis: in essentially tacrolimus or cyclosporine in combination with methotrexate. |
|
Interventions/Control_3 | ||
Interventions/Control_4 | ||
Interventions/Control_5 | ||
Interventions/Control_6 | ||
Interventions/Control_7 | ||
Interventions/Control_8 | ||
Interventions/Control_9 | ||
Interventions/Control_10 |
Eligibility | ||||
Age-lower limit |
|
|||
Age-upper limit |
|
|||
Gender | Male and Female | |||
Key inclusion criteria | Inclusion criteria
1) 1) AML (acute promyelocytic leukemia, AML which developed in patients with Down syndrome, secondary AML, AML which developed in patients with myelodysplastic syndrome, NK/myeloid leukemia and granulocytic leukemia are excluded) 2) Cases registered in the prospective study in JPLSG (JPLSG CHM-14) 3) Patients with high-risk AML in first complete remission or bone marrow-relapsed patients with AML in second complete remission 4) High-risk AML Any of the following a) Unfavorable chromosome abnormality including -7, del(5q)/-5, t(16;21)(p11;q22)/FUS-ERG, t(9;22)(q34;q11.2)/BCR-ABL1 or t(6;11)(q27;q23)/MLL-MLLT4(AF6), or unfavorable genetic abnormality including FLT3-ITD or NUP98-NSD1 b) Blast ratio >=5% in the bone marrow (M2/M3 marrow) after the first induction therapy c) Extramedullary lesions after the first induction therapy 5) Patients less than 18 years at the initial diagnosis in first remission, or patients less than 20 years at the relapse diagnosis in second remission 6) Written informed consent has been acquired from patients and/or persons with parental authority. 7) Cases in which a suitable donor is available and hematopoietic cell transplantation is considered to be mandatory 8) Patients whose performance status are 0 or 2 by ECOG criteria 9) Patients who satisfactory meet all of the following criteria about organ functions within 28 days prior to registration a) Patients without uncontrolled cardiac failure and ejection fraction of left ventricle >= 50% by UCG b) %VC >= 50% and FEV1.0% >= 50%, or SpO2 >= 95% by room air if pulmonary function tests are impossible c) AST/ALT < 5 x upper limit of normal range (CTCAE < grade 2) d) Patients without uncontrolled renal failure and sCr < 2 x upper limit of normal range |
|||
Key exclusion criteria | Exclusion criteria
1) Patients who have extramedullary lesions at registry 2) Patients who have prior radiation therapy 3) Patients who have prior hematopoietic cell transplantation 4) Patients who have poorly controlled infectious disease 5) Patients who have psychiatric disorder 6) Patients who have coinciding malignancies 7) Patients who have an episode of hypersensitivity reactions against drugs used in conditioning regimens and/or GVHD prophylaxis 8) Pregnant women or women who may be pregnant 9) Patients who are considered as inappropriate for this trial by attending physicians |
|||
Target sample size | 66 |
Research contact person | |||||||
Name of lead principal investigator |
|
||||||
Organization | Tokai University, School of Medicine | ||||||
Division name | Department of Cell Transplantation and Regenerative Medicine | ||||||
Zip code | |||||||
Address | 143, Shimokasuya, Isehara, Japan | ||||||
TEL | 0463-93-1121 | ||||||
yabeh@is.icc.u-tokai.ac.jp |
Public contact | |||||||
Name of contact person |
|
||||||
Organization | Kyoto City Hospital / Graduate School of Medicine, Kyoto University | ||||||
Division name | Department of Pediatrics / Department of Pediatrics | ||||||
Zip code | |||||||
Address | 1-2, Higashitakada-cho, Mibu, Nakagyou-ku, Kyoto / 54, Kawahara-cho, Shogoin, Sakyou-ku, Kyoto | ||||||
TEL | 075-311-5311.075-751-3290 | ||||||
Homepage URL | http://jplsg.jp/menu0_contents/index_menu_0.htm | ||||||
ishidah@koto.kpu-m.ac.jp |
Sponsor | |
Institute | Japan Children's Cancer Group (JCCG) |
Institute | |
Department |
Funding Source | |
Organization | Japan Agency for Medical Research and Development |
Organization | |
Division | |
Category of Funding Organization | Japanese Governmental office |
Nationality of Funding Organization | Japan |
Other related organizations | |
Co-sponsor | |
Name of secondary funder(s) |
IRB Contact (For public release) | |
Organization | |
Address | |
Tel | |
Secondary IDs | |
Secondary IDs | NO |
Study ID_1 | |
Org. issuing International ID_1 | |
Study ID_2 | |
Org. issuing International ID_2 | |
IND to MHLW |
Institutions | |
Institutions | 日本小児血液・がん研究組織参加施設 |
Other administrative information | |||||||
Date of disclosure of the study information |
|
Related information | |
URL releasing protocol | |
Publication of results | Unpublished |
Result | |
URL related to results and publications | |
Number of participants that the trial has enrolled | |
Results | |
Results date posted | |
Results Delayed | |
Results Delay Reason | |
Date of the first journal publication of results | |
Baseline Characteristics | |
Participant flow | |
Adverse events | |
Outcome measures | |
Plan to share IPD | |
IPD sharing Plan description |
Progress | |||||||
Recruitment status | Enrolling by invitation | ||||||
Date of protocol fixation |
|
||||||
Date of IRB | |||||||
Anticipated trial start date |
|
||||||
Last follow-up date | |||||||
Date of closure to data entry | |||||||
Date trial data considered complete | |||||||
Date analysis concluded |
Other | |
Other related information |
Management information | |||||||
Registered date |
|
||||||
Last modified on |
|
Link to view the page | |
URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000031865 |
Research Plan | |
Registered date | File name |
Research case data specifications | |
Registered date | File name |
Research case data | |
Registered date | File name |